ClinicalTrials.gg
CompletedNCT06516302Updated Oct 29, 2026

A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps

A Phase 3 interventional study of GR1802 and Placebo in Chronic Rhinosinusitis With Nasal Polyps, sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd. (part of Chongqing Genrix Biopharmaceutical Co., Ltd) · Phase 3, Interventional, and Treatment

How we know

Updated Oct 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.

Enrollment
11th of 43
228 · median 90
Started
2024
with 5 others
Phase 3
14 of 46
3 open now
Registered
27th of 46
by date
Lead sponsor
2 of 46
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Among the 46 studies in Nasal Polyps with a site in China, this one is the 11th largest by enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2024, is one of 14 in phase 3, and was the 27th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Nasal Polyps with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if GR1802 works to treat severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. It will also learn about the safety of GR1802. The main questions it aims to answer are:

  1. Does GR1802 reduce the need for surgery and systemic corticosteroid use?
  2. What medical problems do participants have when taking GR1802?

Researchers will compare GR1802 to a placebo (a look-alike substance that contains no drug) to see if GR1802 works to treat CRSwNP.

Participants will:

Take GR1802 or a placebo once every 2 weeks for 13months. Visit the clinic once every 2 weeks for checkups and tests. Keep a diary of their symptoms and the dosage and number of times they use mometasone furoate nasal spray.

Read the detailed description

A randomized, double-blind, placebo-controlled, multi-center clinical trial was designed. The clinical trial was divided into 4 stages: screening/introduction period, double-blind treatment period , maintenance treatment period and safety follow-up period.

The clinical trial aimed to evaluate the efficacy, safety and immunogenicity of GR1802 injection in CRSwNP participants.

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed as CRSwNP and treated with systemic within 2 years before screening; and/or those who had undergone surgery for nasal polyps before screening.
  • An endoscopic bilateral NPS at screening/lead-in period and the baseline period of at least 5 out of a maximum score of 8 (with a minimum socre of 2 in each nasal cavity).
  • Nasal congestion/blockade/obstruction with moderate or severe symptom severity at at screening period (score 2 or 3 ) .
  • Willing to sign an , able to comply with clinic visits and study-related procedures as per protocol.

Exclusion criteria

Exclusion Criteria:

  • Biologic therapy within 5 half-lives or within 10 weeks before baseline.
  • Anti-IL-4Rα antibody before screening.
  • An experimental drug within 5 half-lives or 1 months before baseline.
  • Systemic to treat inflammatory disease or disease within 2 months or 5 half-lives before baseline.
  • Initiation of allergen immunotherapy within 3 months before screening.
  • Participants receiving leukotriene antagonist/modifier before screening unless on continous treatment for at least 30 days.
  • Participants with 50% or less of predicted normal were excluded.
  • Participants who have undergone any intranasal and/or sinus surgery within 6 months before screening.
  • Acute sinusitis or upper respiratory infection within a defined time period before screening.
  • A nasal cavity tumor (malignant or benign).
  • Evidence of fungal rhinosinusitis.
  • Presence of another diagnosis associated with nasal polyps (i.e., eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, Young's syndrome, cystic fibrosis).
  • Rhinitis medicamentosa.
  • Nasal septal deviation occluding at least one nostril.
  • Antrochoanal polyps.
  • Pregnant or lactating woman.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    GR1802 group

    GR1802 300mg is administrated every 2 weeks (first dose doubled) for a total of 26 doses, of which an additional 2 ml of placebo is given at week 24.

    Drug: GR1802

  • Placebo comparator
    placebo group

    Placebo is administered every 2 weeks for the first 16 weeks. GR1802 is given every 2 weeks from week 24 to W50.

    Drug: Placebo

Interventions

  • DrugGR1802

    GR1802 will be administered SC.

  • DrugPlacebo

    The placebo will be administered SC.

06

What researchers measure

Primary outcomes

  1. Change from baseline in nasal polyps score at week 24.

    Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

    Time frame: At week 24

  2. Change from baseline in nasal congestion score at week 24.

    Nasal congestion score (0-3), higher score means worse nasal symptom.

    Time frame: At week 24

Secondary outcomes

  1. Change from baseline in reduction/loss of smell at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 and 60.

    The reduction/loss of smell severity was reported by the participant on a daily basis using a 0 to 3 categorical scale. Higher score means a worse sense of smell.

    Time frame: From baseline to week 60

  2. Change from baseline in nasal discharge (anterior/posterior) at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 and 60.

    The nasal discharge severity was reported by the participant on a daily basis using a 0 to 3 categorical scale. Higher score means a worse nasal symptom.

    Time frame: From baseline to week 60

  3. Change from baseline in Total Nasal Symptom Score (TNSS) at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 and 60.

    TNSS score (0-9). Higher score means worse nasal symptom.

    Time frame: From baseline to week 60

  4. Change from baseline in nasal endoscopy nasal polyps score in participants with a high power field of vision < 55 eosinophil granulocytes in nasal polyp tissue at week 24.

    Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

    Time frame: At week 24

  5. Change from baseline in nasal congestion score in participants with a high power field of vision < 55 eosinophil granulocytes in nasal polyp tissue at week 24.

    Nasal congestion score (0-3), higher score means worse nasal symptom.

    Time frame: At week 24

  6. Change from baseline in nasal polyps score at weeks 2、4、8、16、32、40、52 and 60.

    Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

    Time frame: From baseline to week 60

  7. Proportion of participants with improvement by at least 1 point in nasal polyps score at weeks 2、4、8、16、24、32、40、52 and 60.

    Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

    Time frame: From baseline to week 60

  8. Proportion of participants with improvement by at least 2 point in nasal polyps score at weeks 2、4、8、16、24、32、40、52 and 60.

    Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

    Time frame: From baseline to week 60

  9. Time to first response (≥1 point improvement) in nasal polyps score.

    Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

    Time frame: From baseline to week 60

  10. Change from baseline in nasal congestion score at weeks 4、8、12、16、20、28、32、36、40、44、48、52、56 and 60.

    Nasal congestion score (0-3), higher score means worse nasal symptom.

    Time frame: From baseline to week 60

  11. Proportion of participants with improvement by at least 1 point in nasal congestion score at weeks 4、8、12、16、20、24、28、32、36、40、44、48、52、56 and 60.

    Nasal congestion score (0-3), higher score means worse nasal symptom.

    Time frame: From baseline to week 60

  12. Proportion of participants with improvement by at least 2 point in nasal congestion score at weeks 4、8、12、16、20、24、28、32、36、40、44、48、52、56 and 60.

    Nasal congestion score (0-3), higher score means worse nasal symptom.

    Time frame: From baseline to week 60

  13. Change from baseline in Lund-Mackay score at week 24 and 52.

    The range of LM score is 0-24. Higher score means worse rhinosinusitis.

    Time frame: From baseline to week 60

  14. Change from baseline in 22-item Sinonasal Outcome Test (SNOT-22) at weeks 2, 4, 8, 16, 24, 32, 40, 52 and 60.

    The range of SNOT-22 score is 0 to 110. Higher scores indicating more severe disease.

    Time frame: From baseline to week 60

  15. Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT) at weeks 2, 4, 16, 24, 32, 40, 52 and 60.

    UPSIT score (0-40). Higher score means better sense of smell.

    Time frame: From baseline to week 60

  16. Change from baseline in five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) at weeks 4、16、24、40、52 and 60.

    The EQ-5D-5L descriptive system comprises five dimensions (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION), and each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. The respondent is asked to indicate his/her health state by checking the box next to the most appropriate response level for each of the five dimensions.

    Time frame: From baseline to week 60

  17. Safety parameters.

    Incidence of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious AEs (TESAEs), etc.

    Time frame: From baseline to week 60

  18. Pharmacokinetics, include Ctrough, etc.

    GR1802 concentrations were measured in CRSwNP population using sparse sampling (samples collected at predose, during treatment, and the follow up period).

    Time frame: From baseline to week 60

  19. Pharmacodynamics.

    Levels of the type 2 inflammation biomarkers were assessed as markers for disease activity/severity.

    Time frame: From baseline to week 60

  20. Immunogenicity, include ADA and Nab.

    Anti GR1802 antibody status was determined at baseline and at prespecified time points.

    Time frame: From baseline to week 60

07

Study locations

1 site
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Jun 2026, 20 months.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 20 months is close to that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Mar 2026 → Jun 2026 and completion Oct 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Jul 23, 2024
StartActual
Sep 19, 2024
Primary completionActual
Jun 12, 2026was Mar 2026
CompletionActual
Aug 13, 2026was Oct 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 29, 2026
Primary completion
Mar 2026→Jun 12, 2026 (actual)
Oct 29, 2026
Study completion
Oct 2026→Aug 13, 2026 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Active, not recruiting→Completed
    Primary completion Mar 2026→Jun 12, 2026 (now actual)
    Study completion Oct 2026→Aug 13, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06516302
Responsible party
Sponsor
First posted
Jul 23, 2024
Start date
Sep 19, 2024
Primary completion
Jun 12, 2026
Completion
Aug 13, 2026
Last update
Oct 29, 2026

Study contacts

Luo Zhang, Doctor
principal investigator · Beijing Tongren Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion